OBJECTIVES: To compare the antimicrobial susceptibility of Prevotella spp. isolated from cystic fibrosis (CF) and non-CF patients and analyse the impact of antibiotic prescribing in the preceding year on resistance amongst CF isolates. METHODS: The susceptibility of 80 CF Prevotella isolates to 12 antibiotics was compared with that of 50 Prevotella isolates from invasive infections in people who did not have CF and 27 Prevotella isolates from healthy controls. RESULTS: All isolates were susceptible to chloramphenicol, meropenem and piperacillin/tazobactam, with only four isolates resistant to metronidazole. However, resistance to amoxicillin, ceftazidime and tetracycline was apparent in all groups. Significant differences in clindamycin resistance (UK CF, 56%; UK invasive, 10%) and co-amoxiclav non-susceptibility (UK CF, 32%; UK invasive, 12%) were observed between UK CF and UK invasive isolates. The likelihood of non-susceptibility to clindamycin and co-amoxiclav in UK CF isolates was 5.5-fold and 2.5-fold higher relative to that in UK invasive isolates, respectively. Azithromycin MICs were also significantly higher for CF isolates (P < 0.001), which was associated with current prescription of azithromycin. More than 50% of clinical isolates tested in this study were β-lactamase positive. CONCLUSIONS: This study profiles antibiotic susceptibility in Prevotella spp. in CF and demonstrates that meropenem, piperacillin/tazobactam, chloramphenicol and metronidazole are likely to be the most effective antibiotics if treatment is indicated.
OBJECTIVES: To compare the antimicrobial susceptibility of Prevotella spp. isolated from cystic fibrosis (CF) and non-CF patients and analyse the impact of antibiotic prescribing in the preceding year on resistance amongst CF isolates. METHODS: The susceptibility of 80 CF Prevotella isolates to 12 antibiotics was compared with that of 50 Prevotella isolates from invasive infections in people who did not have CF and 27 Prevotella isolates from healthy controls. RESULTS: All isolates were susceptible to chloramphenicol, meropenem and piperacillin/tazobactam, with only four isolates resistant to metronidazole. However, resistance to amoxicillin, ceftazidime and tetracycline was apparent in all groups. Significant differences in clindamycin resistance (UK CF, 56%; UK invasive, 10%) and co-amoxiclav non-susceptibility (UK CF, 32%; UK invasive, 12%) were observed between UK CF and UK invasive isolates. The likelihood of non-susceptibility to clindamycin and co-amoxiclav in UK CF isolates was 5.5-fold and 2.5-fold higher relative to that in UK invasive isolates, respectively. Azithromycin MICs were also significantly higher for CF isolates (P < 0.001), which was associated with current prescription of azithromycin. More than 50% of clinical isolates tested in this study were β-lactamase positive. CONCLUSIONS: This study profiles antibiotic susceptibility in Prevotella spp. in CF and demonstrates that meropenem, piperacillin/tazobactam, chloramphenicol and metronidazole are likely to be the most effective antibiotics if treatment is indicated.
Entities:
Keywords:
anaerobic bacteria; antimicrobial susceptibility; β-lactamase production
Authors: J Kirk Harris; Mary Ann De Groote; Scott D Sagel; Edith T Zemanick; Robert Kapsner; Churee Penvari; Heidi Kaess; Robin R Deterding; Frank J Accurso; Norman R Pace Journal: Proc Natl Acad Sci U S A Date: 2007-12-11 Impact factor: 11.205
Authors: Michael M Tunney; Tyler R Field; Thomas F Moriarty; Sheila Patrick; Gerd Doering; Marianne S Muhlebach; Matthew C Wolfgang; Richard Boucher; Deirdre F Gilpin; Andrew McDowell; J Stuart Elborn Journal: Am J Respir Crit Care Med Date: 2008-02-08 Impact factor: 21.405
Authors: Diane M Citron; Ellie J C Goldstein; C Vreni Merriam; Benjamin A Lipsky; Murray A Abramson Journal: J Clin Microbiol Date: 2007-07-03 Impact factor: 5.948
Authors: Anthony A Fodor; Erich R Klem; Deirdre F Gilpin; J Stuart Elborn; Richard C Boucher; Michael M Tunney; Matthew C Wolfgang Journal: PLoS One Date: 2012-09-26 Impact factor: 3.240
Authors: Laura J Sherrard; Bettina Schaible; Kathryn A Graham; Stef J McGrath; Leanne McIlreavey; Joseph Hatch; Matthew C Wolfgang; Marianne S Muhlebach; Deirdre F Gilpin; Thamarai Schneiders; J Stuart Elborn; Michael M Tunney Journal: J Antimicrob Chemother Date: 2014-06-10 Impact factor: 5.790
Authors: Marianne S Muhlebach; Joseph E Hatch; Gisli G Einarsson; Stef J McGrath; Deirdre F Gilipin; Gillian Lavelle; Bojana Mirkovic; Michelle A Murray; Paul McNally; Nathan Gotman; Sonia Davis Thomas; Matthew C Wolfgang; Peter H Gilligan; Noel G McElvaney; J Stuart Elborn; Richard C Boucher; Michael M Tunney Journal: Eur Respir J Date: 2018-07-11 Impact factor: 16.671
Authors: Laura J Sherrard; Stef J McGrath; Leanne McIlreavey; Joseph Hatch; Matthew C Wolfgang; Marianne S Muhlebach; Deirdre F Gilpin; J Stuart Elborn; Michael M Tunney Journal: Int J Antimicrob Agents Date: 2015-12-29 Impact factor: 5.283
Authors: Katherine O'Neill; Judy M Bradley; Elinor Johnston; Stephanie McGrath; Leanne McIlreavey; Stephen Rowan; Alastair Reid; Ian Bradbury; Gisli Einarsson; J Stuart Elborn; Michael M Tunney Journal: PLoS One Date: 2015-05-20 Impact factor: 3.240
Authors: Sebastian Böttger; Silke Zechel-Gran; Daniel Schmermund; Philipp Streckbein; Jan-Falco Wilbrand; Michael Knitschke; Jörn Pons-Kühnemann; Torsten Hain; Markus Weigel; Hans-Peter Howaldt; Eugen Domann; Sameh Attia Journal: Microorganisms Date: 2021-06-16
Authors: Elizabeth A Baldwin; Marina Walther-Antonio; Douglas J Creedon; Nicholas Chia; Allison M MacLean; Daryl M Gohl; Kenneth B Beckman; Jun Chen; Bryan White Journal: PeerJ Date: 2015-11-26 Impact factor: 2.984